Altogether, through the in‐depth investigation of CAFs, we identified immune‐active CAFs that express two potential tyrosine kinase receptors (FGFR1 and PDGFRΒ) in the HRD group, as well as “indolent CAFs” that form an immune barrier in the HRP group, providing clinical insights for the exploration of novel therapeutic strategies targeting CAFs. The gene discussed is PDGFRB; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.